Analyst Consensus ?
ConsensusBuy33 ratings
Bullish2472.7%
Neutral721.2%
Bearish26.1%
Align Technology, Inc. · ALGN · FY2025 Q3 · Calendar Q4 2025
Align Technology: Q3 growth and raised outlook offset regional risks
The latest analysis supports a constructive but qualified view: international clear-aligner growth, digital workflow products, DSO partnerships and improved guidance strengthen the growth case, while North American retail weakness, pricing pressure and China VBP remain material counterweights.
Reported After market closeNASDAQHealthcare
$10.41B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.61
Consensus $2.40
EPS surprise
+8.8%
Reported versus consensus
Reported revenue
$995.7M
Consensus $976.4M
Revenue surprise
+2.0%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+4.9%
Event window
SPY move
-1.1%
Same window
Abnormal move
+6.0%
Stock minus SPY
Volume
3.1×
Versus trailing sessions
Subsequent drift
+6.3%
Up to 20 sessions
ALGNSPY benchmark
Ask FN2 about ALGN FY2025 Q3
Transcript, numbers and history already loaded
Why did ALGN rise 4.9% after beating EPS estimates in FY2025 Q3?What changed in ALGN's guidance and outlook in FY2025 Q3?Give me the bull and bear case for ALGN after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management tone shifted from cautious to confident, guidance sentiment moved from lowered to raised, and the company emphasized stronger international volume, new digital workflow launches and sequential Q4 revenue and margin expansion.
Guidance delta
Improved from the prior quarter: management raised its Q4 outlook and projected sequential revenue and margin expansion.
Key takeaways
- Clear Aligner volume grew roughly 5% year over year, led by international teens and kids demand.
- Non-GAAP operating margin of 23.9% exceeded the 22% outlook.
- Systems & Services revenue declined with seasonal scanner timing, while total iTero units rose 12% year over year.
- Management highlighted iTero Lumina, ClinCheck Live Plan, exocad ART and the Invisalign Palatal Expander.
- North American retail demand remained a constraint despite international and DSO channel growth.
Management priorities
- Expand international volume, including APAC and EMEA.
- Broaden adoption of iTero Lumina and wand upgrades.
- Roll out ClinCheck Live Plan and exocad ART.
- Use DSO and financing partnerships to support patient uptake.
- Invest in technology upgrades and manufacturing capacity.
Follow ALGN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$145.25Current
$140Low
$291.62Average
$790High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Neutral | Neutral | Maintain | Jul 23, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Apr 30, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 30, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 24, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Apr 21, 2026 |
| Barclays | Overweight | Equal Weight | Upgrade | Mar 17, 2026 |
| HSBC | Buy | Hold | Upgrade | Feb 9, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 5, 2026 |
| Stifel | Buy | Buy | Maintain | Feb 5, 2026 |
| Jefferies | Hold | Buy | Downgrade | Oct 10, 2025 |
| Needham | Hold | Hold | Maintain | May 1, 2025 |
| Leerink Partners | Outperform | Market Perform | Upgrade | Jan 6, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Dec 13, 2024 |
| Baird | Outperform | Outperform | Maintain | Oct 24, 2024 |
| OTR Global | Mixed | Positive | Downgrade | Jun 4, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Feb 2, 2024 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jul 28, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | May 4, 2022 |
| Wolfe Research | Outperform | Outperform | Maintain | Jul 29, 2021 |
| BNP Paribas | Outperform | Outperform | Maintain | Jul 8, 2021 |
| SVB Leerink | Outperform | Outperform | Maintain | Apr 29, 2021 |
| Berenberg | Buy | Hold | Upgrade | Apr 22, 2021 |
| Guggenheim | Buy | Buy | Maintain | Apr 18, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 26, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | May 24, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | May 24, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 8, 2017 |
| Bank of America | Buy | Neutral | Upgrade | Jul 28, 2017 |
| Roth Capital | Buy | Buy | Maintain | Mar 23, 2016 |
| JMP Securities | Market Perform | Market Outperform | Downgrade | Jan 30, 2015 |
| Barrington Research | Outperform | Market Perform | Upgrade | Apr 7, 2014 |
| Cantor Fitzgerald | Buy | Hold | Upgrade | Oct 18, 2013 |
| Janney Capital | Buy | Buy | Maintain | Jan 29, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $145.26. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $189 | $166.86 | +30.1% | Jul 23, 2026 |
| BMO Capital | Vik Chopra | $209 | $174.68 | +43.9% | Jul 8, 2026 |
| Morgan Stanley | Analyst unavailable | $188 | $190.67 | +29.4% | Apr 24, 2026 |
| Piper Sandler | Jason Bednar | $235 | $191.66 | +61.8% | Apr 21, 2026 |
| Barclays | Glen Santangelo | $200 | $187.68 | +37.7% | Feb 25, 2026 |
| HSBC | Sidharth Sahoo | $200 | $187.6 | +37.7% | Feb 9, 2026 |
| Evercore ISI | Elizabeth Anderson | $200 | $176.27 | +37.7% | Feb 5, 2026 |
| Stifel Nicolaus | Analyst unavailable | $210 | $161.3 | +44.6% | Feb 5, 2026 |
| Wells Fargo | Analyst unavailable | $200 | $173.75 | +37.7% | Feb 5, 2026 |
| Robert W. Baird | Analyst unavailable | $218 | $161.3 | +50.1% | Feb 5, 2026 |
| UBS | Analyst unavailable | $185 | $161.3 | +27.4% | Feb 5, 2026 |
| Piper Sandler | Analyst unavailable | $220 | $161.3 | +51.5% | Feb 5, 2026 |
| Mizuho Securities | Steven Valiquette | $200 | $171.49 | +37.7% | Jan 20, 2026 |
| Barclays | Analyst unavailable | $170 | $157.68 | +17.0% | Dec 8, 2025 |
| Stifel Nicolaus | Jonathan Block | $200 | $141.55 | +37.7% | Oct 30, 2025 |
| Evercore ISI | Analyst unavailable | $170 | $131.91 | +17.0% | Oct 30, 2025 |
| Piper Sandler | Jason Bednar | $200 | $131.91 | +37.7% | Oct 30, 2025 |
| Piper Sandler | Jason Bednar | $190 | $135.98 | +30.8% | Oct 23, 2025 |
| UBS | Analyst unavailable | $155 | $128.43 | +6.7% | Oct 16, 2025 |
| Mizuho Securities | Analyst unavailable | $170 | $125.79 | +17.0% | Oct 13, 2025 |
| Jefferies | Analyst unavailable | $140 | $131.87 | -3.6% | Oct 10, 2025 |
| Evercore ISI | Elizabeth Anderson | $160 | $131.12 | +10.2% | Oct 8, 2025 |
| Mizuho Securities | Analyst unavailable | $210 | $203.57 | +44.6% | Jul 31, 2025 |
| Morgan Stanley | Analyst unavailable | $154 | $142.5 | +6.0% | Jul 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $275 | $207.66 | +89.3% | Oct 24, 2024 |
| Piper Sandler | Jason Bednar | $275 | $221.06 | +89.3% | Oct 24, 2024 |
| Leerink Partners | Michael Cherny | $235 | $207.66 | +61.8% | Oct 24, 2024 |
| Evercore ISI | Elizabeth Anderson | $250 | $207.66 | +72.1% | Oct 24, 2024 |
| Piper Sandler | Jason Bednar | $285 | $216.05 | +96.2% | Oct 17, 2024 |
| Stifel Nicolaus | Jonathan Block | $285 | $229.65 | +96.2% | Oct 11, 2024 |
| Goldman Sachs | Charles Perron-Piche | $225 | $231.04 | +54.9% | Oct 10, 2024 |
| Evercore ISI | Elizabeth Anderson | $270 | $234.85 | +85.9% | Oct 8, 2024 |
| Piper Sandler | Jason Bednar | $315 | $226.05 | +116.9% | Jul 25, 2024 |
| Robert W. Baird | Jeff Johnson | $325 | $251.6 | +123.7% | Jul 22, 2024 |
| Piper Sandler | Jason Bednar | $330 | $242.61 | +127.2% | Jun 21, 2024 |
| Piper Sandler | Jason Bednar | $375 | $305 | +158.2% | Apr 25, 2024 |
| Robert W. Baird | Jeff Johnson | $370 | $313.78 | +154.7% | Apr 25, 2024 |
| Stifel Nicolaus | Jonathan Block | $400 | $300.14 | +175.4% | Apr 18, 2024 |
| Stifel Nicolaus | Jonathan Block | $350 | $314.35 | +141.0% | Mar 15, 2024 |
| Piper Sandler | Jason Bednar | $355 | $320.69 | +144.4% | Mar 13, 2024 |
| Piper Sandler | Jason Bednar | $340 | $257.3 | +134.1% | Sep 9, 2022 |
| Stifel Nicolaus | Jonathan Block | $375 | $252.07 | +158.2% | Jul 26, 2022 |
| UBS | Analyst unavailable | $500 | $361.35 | +244.2% | Apr 26, 2022 |
| Piper Sandler | Analyst unavailable | $600 | $395.05 | +313.1% | Apr 21, 2022 |
| Jefferies | Brandon Couillard | $635 | $446.41 | +337.2% | Apr 3, 2022 |
| Leerink Partners | Richard Newitter | $770 | $621.87 | +430.1% | Jul 28, 2021 |
| Stephens | Chris Cooley | $700 | $627.19 | +381.9% | Jul 9, 2021 |
| BNP Paribas | Julien Ouaddour | $790 | $616.79 | +443.9% | Jul 8, 2021 |
Track every rating change on ALGN the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAlign Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth).…
Historical context
All ALGN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
- MUFY2026 Q4 · September 30, 2026+5.4% EPS+0.0% move
- CCLFY2026 Q3 · September 29, 2026+5.9% EPS+13.4% move
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
Get the ALGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
- Polygon adjusted daily market bars · 2026-10-01T15:16:06.078617+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-01T15:16:06.075686+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-01. For educational purposes only; not investment advice.